NASDAQ:MCRBSeres Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seres Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.45 +0.11 (+3.29 %) (As of 04/9/2020 03:53 PM ET) Add Compare Share Today's Range$3.35Now: $3.45▼$3.5750-Day Range$2.64MA: $3.32▼$3.8252-Week Range$2.02Now: $3.45▼$7.39Volume17,274 shsAverage Volume343,144 shsMarket Capitalization$245.47 millionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Seres Therapeutics has a potential upside of 142.9% from its current price of $3.50.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesSeres Therapeutics has received 468 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSeres Therapeutics has received 320 “underperform” votes. (Add your “underperform” vote.)Community SentimentSeres Therapeutics has received 59.39% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote “Outperform” if you believe MCRB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.00% of the stock of Seres Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.78% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to grow by 34.38% in the coming year, from ($0.96) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MCRB Previous Symbol CUSIPN/A CIK1609809 Webhttp://www.serestherapeutics.com/ Phone617-945-9626Debt Debt-to-Equity RatioN/A Current Ratio2.18 Quick Ratio2.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.51 million Price / Sales7.11 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-5.00Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-70,280,000.00 Net Margins-203.68% Return on EquityN/A Return on Assets-53.98%Miscellaneous Employees145 Outstanding Shares71,150,000Market Cap$245.47 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive MCRB News and Ratings via Email Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MCRB Rates by TradingView Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions How has Seres Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MCRB stock has increased by 32.6% and is now trading at $3.50. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Seres Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seres Therapeutics. When is Seres Therapeutics' next earnings date? Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Seres Therapeutics. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics Inc (NASDAQ:MCRB) issued its earnings results on Monday, March, 2nd. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.03. The biotechnology company had revenue of $7.62 million for the quarter, compared to analysts' expectations of $6.82 million. View Seres Therapeutics' earnings history. What price target have analysts set for MCRB? 6 equities research analysts have issued 12 month target prices for Seres Therapeutics' shares. Their forecasts range from $4.00 to $15.00. On average, they expect Seres Therapeutics' stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price. View analysts' price targets for Seres Therapeutics. What are Wall Street analysts saying about Seres Therapeutics stock? Here are some recent quotes from research analysts about Seres Therapeutics stock: 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/29/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company’s re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects." (5/7/2019) 3. HC Wainwright analysts commented, "We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success." (5/3/2019) Has Seres Therapeutics been receiving favorable news coverage? Media stories about MCRB stock have trended very negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Seres Therapeutics earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutSeres Therapeutics. Who are some of Seres Therapeutics' key competitors? Some companies that are related to Seres Therapeutics include Phibro Animal Health (PAHC), Intra-Cellular Therapies (ITCI), Kiniksa Pharmaceuticals (KNSA), NextCure (NXTC), Aimmune Therapeutics (AIMT), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), Revance Therapeutics (RVNC), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), Akebia Therapeutics (AKBA), Odonate Therapeutics (ODT), Opko Health (OPK), Homology Medicines (FIXX) and Endo International (ENDP). What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), Novavax (NVAX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Alibaba Group (BABA), Anavex Life Sciences (AVXL) and Micron Technology (MU). Who are Seres Therapeutics' key executives? Seres Therapeutics' management team includes the following people: Mr. Eric D. Shaff, Pres, CEO & Director (Age 43)Mr. Marcus Chapman, VP of Fin., Principal Financial & Accounting Officer (Age 48)Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications When did Seres Therapeutics IPO? (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." How do I buy shares of Seres Therapeutics? Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $3.50. How big of a company is Seres Therapeutics? Seres Therapeutics has a market capitalization of $249.03 million and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe. View additional information about Seres Therapeutics. What is Seres Therapeutics' official website? The official website for Seres Therapeutics is http://www.serestherapeutics.com/. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: What is intrinsic value?
